Chronic Obstructive Pulmonary Disease (COPD) Measures Document

Size: px
Start display at page:

Download "Chronic Obstructive Pulmonary Disease (COPD) Measures Document"

Transcription

1 Chronic Obstructive Pulmonary Disease (COPD) Measures Document COPD Version: 3 - covering patients discharged between 01/10/2017 and present. Programme Lead: Jo Higgins Clinical Lead: Dr Paul Albert Number of Measures In Clinical Focus Area (CFA) Clinical Process Measures 5 Data Measures - Mandatory 1 advancing.quality@nhs.net Website: Produced on 21 June 2017

2 Introduction Chronic Obstructive Pulmonary Disease (COPD) is the name for a collection of lung diseases including chronic bronchitis, emphysema and chronic obstructive airways disease. People with COPD have difficulties breathing, primarily due to the narrowing of their airways, this is called airflow obstruction. COPD is characterised by airflow obstruction that is not fully reversible. The airflow obstruction does not change markedly over several months and is usually progressive in the long term. COPD is predominantly caused by smoking. Other factors, particularly occupational exposures, may also contribute to the development of COPD. The airflow obstruction is present because of a combination of airway and parenchymal damage. The damage is the result of chronic inflammation that differs from that seen in asthma and which is usually the result of tobacco smoke. Significant airflow obstruction may be present before the person is aware of it. COPD produces symptoms, disability and impaired quality of life which may respond to pharmacological and other therapies that have limited or no impact on the airflow obstruction. Exacerbations often occur, where there is a rapid and sustained worsening of symptoms beyond normal day-to-day variations. COPD is one of the most common respiratory diseases in the UK. It usually only starts to affect people over the age of 35, although most people are not diagnosed until they are in their 50s. It is thought there are more than 3 million people living with the disease in the UK, of which only about 900,000 have been diagnosed. This is because many people who develop symptoms of COPD do not get medical help because they often dismiss their symptoms as a smoker s cough. Although COPD causes about 25,000 deaths a year in the UK, severe COPD can usually be prevented by making lifestyle changes (NHS Choices). The Advancing Quality COPD measures have been chosen to prompt early recognition and treatment of patients admitted to hospital as an emergency with a COPD exacerbation. The expected outcome is to reduce premature mortality. Page 2

3 Measures In Clinical Focus Area Measure Type Measure ID Clinical Process Measure Data Measure - Mandatory COPD-01 COPD-02 COPD-03 COPD-04 COPD-05 COPD-06 Measure Name Oxygen prescribed and administered within 4 hours of hospital arrival Corticosteroids administered within 4 hours of hospital arrival Bronchodilators administered within 4 hours of hospital arrival Offer smoking cessation advice Review inhaler technique Non-invasive ventilation considered if indicated Page 3

4 Measure ID: Measure Name: COPD-01 Unique Record Identifier: Measure Description: Oxygen prescribed and administered within 4 hours of hospital arrival COPD patients should have oxygen prescribed and administered within 4 hours of hospital arrival. Measure Type: Clinical Process Measure Rationale: An effective treatment to increase the amount of oxygen in the arterial blood to a safe level. Prescribed oxygen as recommended by NICE for those at risk of developing type II respiratory failure. Patients with COPD, especially those who receive high oxygen flow oxygen, are at high risk of hypercapnia leading to type II respiratory failure. In the management of acute exacerbations the options for targeted oxygen prescription are 88-92% or 94-98% or should be administered in line with hospital trust guidelines and policy. Numerator Statement: Number of patients who have had oxygen prescribed and administered within 4 hours of hospital arrival. Denominator Statement: Number of patients who are eligible to have oxygen prescribed and administered within 4 hours of hospital arrival. Measure Reported As: The percentage of eligible patients that had their oxygen prescribed and administered within 4 hours of hospital arrival. Improvement Noted As: An increase in the rate. Data Elements: To be considered complete the following data elements should be recorded for the measure:- Clinical Trial COPD COPD Diagnosis Discharge - within 4 hours Oxygen - administered within 4 hours Oxygen - indicated COPD Oxygen - prescribed Oxygen - saturations performed Palliative Care within 4 hours COPD Transfer from another A&E Dept COPD Measure Exclusions: Documentation in the medical record, by a consultant (or person working as part of the consultant team) that the patient is for palliative care only within 4 hours of arrival Documentation in the medical record that the patient participated in a clinical trial affecting care or treatment related to this AQ measure set Documentation in the medical record that the patient was transferred from another hospital A&E department Documentation in the medical record that the patient left the hospital within 4 hours of arrival Documentation within the medical record that oxygen was not indicated No documentation in the medical record, as part of A&E, MAU or post-take ward round documentation, or as an admission diagnosis/impression for a direct admit patient, that the final diagnosis/impression was of COPD. Page 4

5 Measure ID: Measure Name: COPD-02 Unique Record Identifier: Measure Description: Corticosteroids administered within 4 hours of hospital arrival COPD patients should have corticosteroids administered within 4 hours of hospital arrival. Measure Type: Clinical Process Measure Rationale: An effective treatment to prevent or reduce the symptoms of COPD during exacerbation as recommended by NICE. Corticosteroids should be administered in line with local Hospital Trust guidelines and policy. Numerator Statement: Number of patients that have had corticosteroids administered within 4 hours of hospital arrival. Denominator Statement: Number of patients eligible to have corticosteroids administered within 4 hours of hospital arrival. Measure Reported As: The percentage of eligible patients who received corticosteroids within 4 hours of hospital arrival. Improvement Noted As: An increase in the rate. Data Elements: To be considered complete the following data elements should be recorded for the measure:- Arrival Date COPD Arrival Time COPD Clinical Trial COPD COPD Diagnosis Corticosteroids - reason Corticosteroids Date COPD Corticosteroids Time Discharge - within 4 hours Palliative Care within 4 hours COPD Transfer from another A&E Dept COPD Measure Exclusions: Documentation in the medical record, by a consultant (or person working as part of the consultant team) that the patient is for palliative care only within 4 hours of arrival Documentation in the medical record that the patient participated in a clinical trial affecting care or treatment related to this AQ measure set Documentation in the medical record that the patient was transferred from another hospital A&E department Documentation in the medical record that the patient left the hospital within 4 hours of arrival There is documentation of one or more potential contraindications/reasons for not prescribing a corticosteroid within four hours of hospital arrival. No documentation in the medical record, as part of A&E, MAU or post-take ward round documentation, or as an admission diagnosis/impression for a direct admit patient, that the final diagnosis/impression was of COPD. Page 5

6 Measure ID: Measure Name: COPD-03 Unique Record Identifier: Measure Description: Bronchodilators administered within 4 hours of hospital arrival COPD patients should have bronchodilators administered within 4 hours of hospital arrival. Measure Type: Clinical Process Measure Rationale: An effective treatment to prevent or reduce the symptoms of COPD as recommended by NICE. Bronchodilators should be administered in line with local Hospital Trust guidelines and policy. Numerator Statement: Number of patients that have had bronchodilators administered within 4 hours of hospital arrival. Denominator Statement: Number of patients eligible to have bronchodilators administered within 4 hours of hospital arrival. Measure Reported As: The percentage of eligible patients who received bronchodilators within 4 hours of hospital arrival. Improvement Noted As: An increase in the rate. Data Elements: To be considered complete the following data elements should be recorded for the measure:- Arrival Date COPD Arrival Time COPD Bronchodilator - reason Bronchodilator Date Bronchodilator Time Clinical Trial COPD COPD Diagnosis Discharge - within 4 hours Palliative Care within 4 hours COPD Transfer from another A&E Dept COPD Measure Exclusions: Documentation in the medical record, by a consultant (or person working as part of the consultant team) that the patient is for palliative care only within 4 hours of arrival Documentation in the medical record that the patient participated in a clinical trial affecting care or treatment related to this AQ measure set Documentation in the medical record that the patient was transferred from another hospital A&E department Documentation in the medical record that the patient left the hospital within 4 hours of arrival Documentation In the medical record of a reason/contraindication for not prescribing a bronchodilator within 4 hours of hospital arrival No documentation in the medical record, as part of A&E, MAU or post-take ward round documentation, or as an admission diagnosis/impression for a direct admit patient, that the final diagnosis/impression was of COPD. Page 6

7 Measure ID: Measure Name: COPD-04 Offer smoking cessation advice Unique Record Identifier: Measure Description: COPD patients should be offered smoking cessation advice. This should be during hospitalisation. Measure Type: Clinical Process Measure Rationale: Half of all long-term smokers die early from smoking-related diseases. Men who quit smoking by 30 add 10 years to their life. People who quit at 60 add three years to their life. Stopping smoking can halt progression of COPD. (NHS Choices) The definition of a current smoker includes daily smokers and non-daily smokers (also known as occasional smokers) or anyone who has smoked within the last year. People with COPD who smoke are regularly encouraged to stop and are offered the full range of evidence-based smoking cessation support. Numerator Statement: Number of patients offered smoking cessation advice. Denominator Statement: Number of patients eligible to be offered smoking cessation advice. Measure Reported As: The percentage of eligible patients that were offered smoking advice. Improvement Noted As: An increase in the rate. Data Elements: To be considered complete the following data elements should be recorded for the measure:- Clinical Trial COPD COPD Diagnosis Discharge - within 4 hours Palliative Care within 4 hours COPD Smoker - current COPD Smoking - offer advice Measure Exclusions: Documentation in the medical record, by a consultant (or person working as part of the consultant team) that the patient is for palliative care only within 4 hours of arrival Documentation in the medical record that the patient participated in a clinical trial affecting care or treatment related to this AQ measure set Documentation in the medical record that the patient left the hospital within 4 hours of arrival No documentation in the medical record that the patient smoked within the last 12 months, or unable to determine from the medical record No documentation in the medical record, as part of A&E, MAU or post-take ward round documentation, or as an admission diagnosis/impression for a direct admit patient, that the final diagnosis/impression was of COPD. Page 7

8 Measure ID: Measure Name: COPD-05 Review inhaler technique Unique Record Identifier: Measure Description: COPD patients should have their inhaler technique reviewed prior to discharge Measure Type: Clinical Process Measure Rationale: The correct technique when taking inhaled medications ensures that patients with chronic obstructive pulmonary disease receive the maximum benefit from their medications. Inhaler technique is a clinical assessment of how well a patient is able to use and administer their inhaled medication. This should be witnessed and documented by a clinical member of staff. Numerator Statement: Number of patients who have had their inhaler technique reviewed. Denominator Statement: Number of patients eligible to have their inhaler technique reviewed. Measure Reported As: The percentage of patients that have their inhaler technique reviewed. Improvement Noted As: An increase in the rate. Data Elements: To be considered complete the following data elements should be recorded for the measure:- Clinical Trial COPD COPD Diagnosis Discharge - within 4 hours Inhaler - already on Inhaler - technique reviewed COPD Palliative Care within 4 hours COPD Measure Exclusions: Documentation in the medical record, by a consultant (or person working as part of the consultant team) that the patient is for palliative care only within 4 hours of arrival Documentation in the medical record that the patient participated in a clinical trial affecting care or treatment related to this AQ measure set Documentation in the medical record that the patient left the hospital within 4 hours of arrival No documentation in the medical record that the patient is already on an inhaler therapy No documentation in the medical record, as part of A&E, MAU or post-take ward round documentation, or as an admission diagnosis/impression for a direct admit patient, that the final diagnosis/impression was of COPD. Page 8

9 Measure ID: Measure Name: COPD-06 Non-invasive ventilation considered if indicated Unique Record Identifier: Measure Description: COPD patients should have non-invasive ventilation (NIV) considered if indicated Measure Type: Data Measure - Mandatory Rationale: This data collection measure is only relevant in patients where an ABG was performed. Non-invasive ventilation (NIV) is an alternative to invasive mechanical ventilation for patients who have chronic respiratory insufficiency or respiratory failure and can no longer breathe adequately on their own. NIV provides ventilatory support to a patient through the upper airways. It enhances the breathing process by giving the patient a mixture of air and oxygen from a flow generator through a tightly fitted facial or nasal mask. NIV assists the patient in taking a full breath and helps to maintain an adequate oxygen supply to the body. NIV can provide a safe and effective alternative at an early stage of respiratory failure and provide for gradual weaning and normal eating and communication The benefits of an acute NIV service are likely to be: -Fewer patients referred to intensive care for intubation. -Shorter stays on intensive care. -Fewer deaths of patients with acute respiratory failure. Numerator Statement: Number of patients who were considered for NIV if indicated Denominator Statement: Number of patients who were eligible to be considered for NIV if indicated Measure Reported As: Percentage of patients who were considered for NIV if indicated Data Elements: To be considered complete the following data elements should be recorded for the measure:- ABG - abnormal result ABG - within 4 hours Clinical Trial COPD COPD Diagnosis Discharge - within 4 hours NIV - considered COPD Palliative Care within 4 hours COPD Transfer from another A&E Dept COPD Measure Exclusions: Documentation in the medical record, by a consultant (or person working as part of the consultant team) that the patient is for palliative care only within 4 hours of arrival Documentation in the medical record that the patient participated in a clinical trial affecting care or treatment related to this AQ measure set Documentation in the medical record that the patient was transferred from another hospital A&E department No documentation in the medical record that arterial blood gases (ABG) were completed within 4 hours prior to or after arrival at hospital Documentation in the medical record that the patient left the hospital within 4 hours of arrival No documentation in the medical record that the patients arterial blood gases were abnormal. Page 9

10 No documentation in the medical record, as part of A&E, MAU or post-take ward round documentation, or as an admission diagnosis/impression for a direct admit patient, that the final diagnosis/impression was of COPD. Page 10

11 Appendices I. Data Elements Required for Clinical Focus Area Data Element Definition Source Collected for Measures ABG - abnormal result Documentation in the medical record that the patient had an abnormal arterial blood gas (ABG) result. ABG - within 4 hours Arrival Date COPD Arrival Time COPD Bronchodilator - reason Bronchodilator Date Bronchodilator Time Clinical Trial COPD COPD Diagnosis Corticosteroids - reason Corticosteroids Date COPD Corticosteroids Time Discharge - within 4 hours Inhaler - already on Documentation in the medical record that an arterial blood gas (AGB) test was performed within 4 hours of arrival. The earliest documented date (dd/mm/yyyy) that the patient arrived at the hospital for this spell of care/treatment. The earliest documented time (hh:mm) (24 hour clock) the patient arrived at the hospital. Documentation in the medical record of one of more potential reasons/contraindications for not prescribing a bronchodilator. The earliest date (dd/mm/yyyy) that a bronchodilator was administered. The earliest time (hh:mm) (24 hour clock) that a bronchodilator was administered. Documentation in the medical record that the patient was involved in a clinical trial during this hospital stay, directly affecting AQ Measures (specific to the AQ clinical condition the patient was treated for during this spell of care/treatment). Clinical trials are organised studies to provide large bodies of clinical data for statistically valid evaluation or treatment. These studies are usually rigorously controlled tests of new drugs, invasive medical devices, or therapies on human subjects. Documentation in the medical record as part of A&E, MAU or post-take ward round documentation, or as an admission diagnosis/impression for a direct admit patient, that the final diagnosis/impression was of COPD. Documentation in the medical record of one or more potential reasons/contraindications for not prescribing corticosteroids. The earliest documented date (dd/mm/yyyy) that corticosteroids were administered. The earliest documented time (hh:mm) (24 hour clock) that corticosteroid was administered. It is documented in the medical record that the patient was discharged from the hospital within 4 hours of arrival. Documentation in the medical record that the patient is on inhaler therapy. Hospital data collection COPD-06 COPD-06 COPD-02, COPD-03 COPD-02, COPD-03 COPD-03 COPD-03 COPD-03 COPD-01, COPD-02, COPD-03, COPD-04, COPD-05, COPD-06 COPD-01, COPD-02, COPD-03, COPD-04, COPD-05, COPD-06 COPD-02 COPD-02 COPD-02 COPD-01, COPD-02, COPD-03, COPD-04, COPD-05, COPD-06 COPD-05 Inhaler - technique Documentation in the medical record that the COPD-05 Page 11

12 reviewed COPD patient received an inhaler technique review. NIV - considered COPD Oxygen - administered within 4 hours Oxygen - indicated COPD Oxygen - prescribed Oxygen - saturations performed Palliative Care within 4 hours COPD Smoker - current COPD Documentation in the medical record that the patient was considered for non-invasive ventilation. Documentation in the medical record that oxygen was administered within 4 hours. Documentation in the medical record that oxygen was indicated Documentation in the medical record that oxygen was prescribed. Documentation in the medical record that an oxygen saturation test was performed. Consultant (or person working as part of the consultant team) documentation of palliative care. Palliative care includes attention to the psychological and spiritual needs of the patient and support for the dying patient and the patient's family. It may also be known as advanced care planning or advance care plan in place. Documentation in the medical record that the patient smoked tobacco anytime during the 12 months prior to hospital arrival. Smoking - offer advice Documentation in the medical record that the patient (or carer) was offered smoking cessation advice. Transfer from another A&E Dept COPD Documentation in the medical record that the patient was transferred from another hospital A&E department. COPD-06 COPD-01 COPD-01 COPD-01 COPD-01 COPD-01, COPD-02, COPD-03, COPD-04, COPD-05, COPD-06 COPD-04 COPD-04 COPD-01, COPD-02, COPD-03, COPD-06 Page 12

13 II. Population Identification Criteria with Codes The COPD cohort consists of admitted inpatients with a first episode primary ICD-10 diagnosis code of J44.0 Chronic obstructive pulmonary disease with acute lower respiratory infection and J Chronic obstructive pulmonary disease with acute exacerbation, unspecified Patient classification - 1 Admission method - non elective Excluded - Admission source 51,52,53 Patients >= 18 years old Page 13

14 III. References Bestall, J.C., Paul, E.A., Garrod, R. et al. (1999) Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 54(7), Bourbeau, J., Julien, M., Maltais, F. et al. (2003) Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Archives of Internal Medicine 163(5), Celli, B.R. (2000) The importance of spirometry in COPD and asthma: effect on approach to management. Chest 117(2 Suppl), 15S-9. Cully, J.A., Graham, D.P., Stanley, M.A. et al. (2006) Quality of life in patients with chronic obstructive pulmonary disease and comorbid anxiety or depression. Psychosomatics 47(4), Gallefoss, F. and Bakke, P.S. (2002) Cost-benefit and cost-effectiveness analysis of self-management in patients with COPD--a 1-year follow-up randomized, controlled trial. Respiratory Medicine 96(6), Global Initiative for Chronic Obstructive Lung Disease (2006) Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease. Heffner, J.E., Mularski, R.A. and Calverley, P.M. (2010) COPD performance measures: missing opportunities for improving care. Chest 137(5), Kunik, M.E., Roundy, K., Veazey, C. et al. (2005) Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest 127(4), National Clinical Guideline Centre (2010) Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update of CG12) (full NICE guideline). Clinical guideline 101. National Institute for Health and Clinical Excellence. NHS Scotland (2010) Palliative care in advanced lung disease. NHS Lothian. Robb, E., Jarman, B., Suntharalingam, G. et al. (2010) Using care bundles to reduce in-hospital mortality: quantitative survey. BMJ (Clinical Research Ed) 340, c1234. Royal College of Physicians of London, British Thoracic Society and British Lung Foundation (2008) Report of the National Chronic Obstructive Pulmonary Disease Audit 2008: clinical audit of COPD exacerbations admitted to acute NHS units across the UK. Royal College of Physicians of London. Sullivan SD, Ramsey, S.D. and Lee, T.A. (2000) The economic burden of COPD. Chest 117(2 Suppl), 5S-9. Page 14

15 IV. Algorithms Page 15

16 Page 16

17 Page 17

18 Page 18

19 Page 19

20 Page 20

21 Page 21

22 Page 22

23 Page 23

24 COPD: Advancing Quality Data form Name: Hospital Number: DOB: / / NHS: Ethnicity: Source of Admission Admission Date & Time / / : Discharge Date / / Discharge Destination Discharge Method EXCLUSIONS 1. Palliative care within 4 hours of arrival Yes No If Yes, stop 2. Clinical trial Yes No If Yes, stop 3. Discharged within 4 hours of arrival Yes No If Yes, stop 4. Transferred from another A&E Yes No If Yes, skip 5-14, Arrival date & time / / : 6. COPD diagnosis: by A&E/Post take/direct AD Yes No If no, stop OXYGEN THERAPY 7. Oxygen saturations performed Yes No 8. Oxygen indicated (as per local policy) Yes No If no, skip 9&10 9. Oxygen prescribed Yes No If no, skip Oxygen administered within 4 hours Yes No CORTICOSTEROIDS 11. Reason documented for not administering corticosteroids Yes No If Yes, skip Date & time first corticosteroids administered / / : SMOKING CESSATION 15. Smoked within the last 12 months Yes No If No, skip Offered smoking cessation advice Yes No INHALER TECHNIQUE 17. On Inhaler Therapy Yes No If No, skip Inhaler technique reviewed Yes No DATA COLLECTION ONLY: NIV CONSIDERED 19. ABG performed within 4 hours Yes No If no, skip 20& Abnormal ABG result ph < 7.35 PCO2 >6.5 Yes No If no, skip NIV considered Yes No VALIDATIONS Form completed by Designation Inputted by Date Inputted / / BRONCHODILATORS 13. Reason documented for not administering bronchodilators Yes No If Yes, skip Date & time bronchodilators administered / / : COPD DATA COLLECTION FORM v4.1 Page 24

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE DRAFT NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic obstructive pulmonary disease: the management of adults with chronic obstructive pulmonary disease in primary

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic obstructive pulmonary disease: the management of adults with chronic obstructive pulmonary disease in primary and secondary

More information

Diabetes (DIA) Measures Document

Diabetes (DIA) Measures Document Diabetes (DIA) Measures Document DIA Version: 2.1 - covering patients discharged between 01/07/2016 and present. Programme Lead: Liz Kanwar Clinical Lead: Dr Aftab Ahmad Number of Measures In Clinical

More information

Commissioning for Better Outcomes in COPD

Commissioning for Better Outcomes in COPD Commissioning for Better Outcomes in COPD Dr Matt Kearney Primary Care & Public Health Advisor Respiratory Programme, Department of Health General Practitioner, Runcorn November 2011 What are the Commissioning

More information

Chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease 0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find

More information

Hip Fracture (HFR) Measures Document

Hip Fracture (HFR) Measures Document Hip Fracture (HFR) Measures Document HFR Version: 2 - covering patients discharged between 01/10/2017 and present. Programme Lead: Sam Doddridge Clinical Leads: Ms Phil Thorpe Dr John Tsang Number of Measures

More information

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters

2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized

More information

National COPD Audit Programme

National COPD Audit Programme National COPD Audit Programme Planning for every breath National Chronic Obstructive Pulmonary Disease (COPD) Audit Programme: Primary care audit () 2015 17 Data analysis and methodology Section 4: Providing

More information

What s New in Acute COPD? Dr Nick Scriven Consultant AIM President SAM

What s New in Acute COPD? Dr Nick Scriven Consultant AIM President SAM What s New in Acute COPD? Dr Nick Scriven Consultant AIM President SAM Covering: Basic Definition New assessment criteria Some newer treatments BiPAP Not Covering: Definitions: Chronic Obstructive Pulmonary

More information

Chronic Obstructive Pulmonary Disease (COPD).

Chronic Obstructive Pulmonary Disease (COPD). Chronic Obstructive Pulmonary Disease (COPD). Linde: Living healthcare 02 03 Chronic Obstructive Pulmonary Disease (COPD). A pocket guide for healthcare professionals. COPD the facts Moderate to severe

More information

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see: bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest

More information

Roflumilast (Daxas) for chronic obstructive pulmonary disease

Roflumilast (Daxas) for chronic obstructive pulmonary disease Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended

More information

BTS/ICS Guidelines for the ventilatory management of acute hypercapnic respiratory failure in adults

BTS/ICS Guidelines for the ventilatory management of acute hypercapnic respiratory failure in adults BTS/ICS Guidelines for the ventilatory management of acute hypercapnic respiratory failure in adults British Thoracic Society Intensive Care Society Introduction Acute Hypercapnic Respiratory Failure (AHRF)

More information

QOF indicator area: Chronic Obstructive Pulmonary disease (COPD)

QOF indicator area: Chronic Obstructive Pulmonary disease (COPD) NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Cost impact statement: Chronic Obstructive Pulmonary Disease QOF indicator area:

More information

CARE OF THE ADULT COPD PATIENT

CARE OF THE ADULT COPD PATIENT CARE OF THE ADULT COPD PATIENT Target Audience: The target audience for this clinical guideline is all MultiCare providers and staff including those associated with our Clinically Integrated Network. The

More information

COPD GOLD Guidelines & Barnet inhaler choices. Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust

COPD GOLD Guidelines & Barnet inhaler choices. Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust COPD GOLD Guidelines & Barnet inhaler choices Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust GOLD 2017 Report: Chapters 1. Definition and Overview 2. Diagnosis and Initial

More information

Pathway diagrams Annex F

Pathway diagrams Annex F Pathway diagrams Annex F Fig 1 Asthma: The patient journey Asthma is diagnosed Making the diagnosis of asthma Confirming the diagnosis may depend on history, response to treatment, measurement of airflow

More information

RESPIRATORY CARE IN GENERAL PRACTICE

RESPIRATORY CARE IN GENERAL PRACTICE RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they

More information

COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.

COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. 1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness

More information

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see: bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest

More information

COPD. Breathing Made Easier

COPD. Breathing Made Easier COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought

More information

Managing Exacerbations of COPD (Version 3.0)

Managing Exacerbations of COPD (Version 3.0) Managing Exacerbations of COPD (Version 3.0) Guideline Readership This guideline is intended for use in patients with a confirmed diagnosis of a chronic obstructive pulmonary disease (COPD) exacerbation.

More information

CLINICAL PATHWAY. Acute Medicine. Chronic Obstructive Pulmonary Disease

CLINICAL PATHWAY. Acute Medicine. Chronic Obstructive Pulmonary Disease CLINICAL PATHWAY Acute Medicine Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease Table of Contents (tap to jump to page) INTRODUCTION 1 Scope of this Pathway 1 Pathway Contacts

More information

An Outcomes Strategy for COPD and Asthma: NHS Companion Document IMPACT REPORT

An Outcomes Strategy for COPD and Asthma: NHS Companion Document IMPACT REPORT An Outcomes Strategy for COPD and Asthma: NHS Companion Document IMPACT REPORT 1 DH INFORMATION READER BOX Policy Clinical Estates HR / Workforce Commissioner Development IM & T Management Provider Development

More information

Wales Primary Care COPD Audit

Wales Primary Care COPD Audit Wales Primary Care COPD Audit 2014-15 Next steps for improvement National Chronic Obstructive Pulmonary Disease (COPD) Audit Programme 2016 The audit programme partnership Working in strategic partnership:

More information

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

CHRONIC OBSTRUCTIVE PULMONARY DISEASE CHRONIC OBSTRUCTIVE PULMONARY DISEASE DEFINITION Chronic obstructive pulmonary disease (COPD) is a common preventable and treatable disease characterized by airflow limitation that is usually progressive

More information

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES

JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam

More information

CHRONIC OBSTRUCTIVE PULMONARY DISEASE

CHRONIC OBSTRUCTIVE PULMONARY DISEASE CHRONIC OBSTRUCTIVE PULMONARY DISEASE Chronic Obstructive Pulmonary Disease (COPD) is a slowly progressive disease of the airways that is characterized by a gradual loss of lung function. In the U.S.,

More information

Because we care about your health

Because we care about your health Contact us For information on Trust services see www.awp.nhs.uk PALS To make a comment, raise a concern or make a complaint, please contact the Trust s Patient Advice and Liaison Service (PALS). Smoking

More information

Exacerbations of COPD. Dr J Cullen

Exacerbations of COPD. Dr J Cullen Exacerbations of COPD Dr J Cullen Definition An AECOPD is a sustained worsening of the patient s clinical condition from their stable state that is beyond their usual day-to-day variation is acute in onset

More information

Yorkshire & Humber Respiratory Programme Report

Yorkshire & Humber Respiratory Programme Report 2013 NHS Bassetlaw Clinical Commissioning Group Yorkshire & Humber Respiratory Programme Report This report has been produced by the Yorkshire & Humber Respiratory Team. It highlights opportunities that

More information

Chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease National Institute for Clinical Excellence Issue date: February 2004 Quick reference guide Chronic obstructive pulmonary disease Management of chronic obstructive pulmonary disease in adults in primary

More information

VitaBreath. Helping your COPD patients remain active

VitaBreath. Helping your COPD patients remain active VitaBreath Helping your COPD patients remain active COPD: A chronic condition to manage Chronic Obstructive Pulmonary Disease (COPD) is a chronic disorder characterised by consistent airflow obstruction

More information

Admissions to hospital with exacerbations of chronic obstructive pulmonary disease: effect of age related factors and service organisation

Admissions to hospital with exacerbations of chronic obstructive pulmonary disease: effect of age related factors and service organisation 843 CHRONIC OBSTRUCTIVE PULMONARY DISEASE Admissions to hospital with exacerbations of chronic obstructive pulmonary disease: effect of age related factors and service organisation M J Connolly, D Lowe,

More information

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist

Defining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease

More information

Anyone who smokes and/or has shortness of breath and sputum production could have COPD

Anyone who smokes and/or has shortness of breath and sputum production could have COPD COPD DIAGNOSIS AND MANAGEMENT CHECKLIST Anyone who smokes and/or has shortness of breath and sputum production could have COPD Confirm Diagnosis Presence and history of symptoms: Shortness of breath Cough

More information

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease Page 1 of 5 Chronic Obstructive Pulmonary Disease Chronic Obstructive Pulmonary Disease (COPD) is an 'umbrella' term for people with chronic bronchitis, emphysema, or both. With COPD the airflow to the

More information

THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable

THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause

More information

Chronic Obstructive Pulmonary Disease (COPD) Clinical Guideline

Chronic Obstructive Pulmonary Disease (COPD) Clinical Guideline Chronic Obstructive Pulmonary Disease (COPD) Clinical These clinical guidelines are designed to assist clinicians by providing an analytical framework for the evaluation and treatment of patients. They

More information

Acute NIV in COPD and what happens next. Dr Rachael Evans PhD Associate Professor, Respiratory Medicine, Glenfield Hospital

Acute NIV in COPD and what happens next. Dr Rachael Evans PhD Associate Professor, Respiratory Medicine, Glenfield Hospital Acute NIV in COPD and what happens next Dr Rachael Evans PhD Associate Professor, Respiratory Medicine, Glenfield Hospital Content Scenarios Evidence based medicine for the first 24 hrs Who should we refer

More information

Yorkshire & Humber Respiratory Programme Report

Yorkshire & Humber Respiratory Programme Report 2013 NHS Doncaster Clinical Commissioning Group Yorkshire & Humber Respiratory Programme Report This report has been produced by the Yorkshire & Humber Respiratory Team. It highlights opportunities that

More information

HQO s Episode of Care for Chronic Obstructive Pulmonary Disease

HQO s Episode of Care for Chronic Obstructive Pulmonary Disease HQO s Episode of Care for Chronic Obstructive Pulmonary Disease Dr. Chaim Bell, MD PhD FRCPC Ontario Hospital Association Webcast October 23, 2013 Objectives 1. Describe the rationale and methodology for

More information

People with asthma who smoke. The combination of asthma, a chronic airway disease, and smoking increases the risk of COPD even more.

People with asthma who smoke. The combination of asthma, a chronic airway disease, and smoking increases the risk of COPD even more. COPD Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing difficulty, cough, sputum (phlegm) production

More information

Course Handouts & Disclosure

Course Handouts & Disclosure COPD: Disease Trajectory and Hospice Eligibility Terri L. Maxwell PhD, APRN VP, Strategic Initiatives Weatherbee Resources Hospice Education Network Course Handouts & Disclosure To download presentation

More information

Policy position statement Chronic Obstructive Pulmonary Disease (COPD) May 2017 Introduction

Policy position statement Chronic Obstructive Pulmonary Disease (COPD) May 2017 Introduction Policy position statement Chronic Obstructive Pulmonary Disease (COPD) May 2017 Introduction The British Lung Foundation recommends: Improvements to COPD diagnosis speed and accuracy through better symptom

More information

OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING 10/16/2018 DISCLOSURES I have no financial or other disclosures

OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING 10/16/2018 DISCLOSURES I have no financial or other disclosures OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING J. Michael Fuller, MD, MEd, FACP, FCCP Associate Professor of Medicine University of South Carolina Greenville DISCLOSURES I have no financial or other

More information

A breath of fresh air

A breath of fresh air Respiratory Clinical Pathway Team A breath of fresh air Working together to improve respiratory care in the North West Contents Breathing space 3 Respiratory disease - the basics 4 How to prevent admissions

More information

Chronic Obstructive Pulmonary Disease Guidelines and updates

Chronic Obstructive Pulmonary Disease Guidelines and updates Chronic Obstructive Pulmonary Disease Guidelines and updates October 20, 2018 Saratoga Springs, NY COPD (Chronic obstructive pulmonary disease) is a major cause of mortality and morbidity in the United

More information

information Chronic Obstructive Pulmonary Disease - COPD (1 of 5) What is COPD? What is going on in my lungs? What are the symptoms of COPD?

information Chronic Obstructive Pulmonary Disease - COPD (1 of 5) What is COPD? What is going on in my lungs? What are the symptoms of COPD? information If you need this information in another language or medium (audio, large print, etc) please contact the Patient Advice and Liaison Service (PALS) on 0800 374 208 email: pal.service@ salisbury.nhs.uk.

More information

Referring for specialist respiratory input. Dr Melissa Heightman Consultant respiratory physician, UCLH,WH, CNWL

Referring for specialist respiratory input. Dr Melissa Heightman Consultant respiratory physician, UCLH,WH, CNWL Referring for specialist respiratory input Dr Melissa Heightman Consultant respiratory physician, UCLH,WH, CNWL Respiratory Specialist- who? GPSI Community Team Secondary Care Respiratory physician and

More information

How to treat COPD? What is the mechanism of dyspnea? Smoking cessation

How to treat COPD? What is the mechanism of dyspnea? Smoking cessation : The Increasing Role of the FP Alan Kaplan, MD, CCFP(EM) Presented at the Primary Care Today: Education Conference and Medical Exposition, Toronto, Ontario, May 2006. Chronic obstructive pulmonary disease

More information

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD) Chronic Obstructive Pulmonary Disease (COPD) Health Promotion and Education Program Rev. 2014 2014, MMM Healthcare, Inc. - PMC Medicare Choice, Inc. Reproduction of this material is prohibited. MP-HEP-PPT-200-01-021914-E

More information

Changing Healthcare Forever mycopd

Changing Healthcare Forever mycopd Changing Healthcare Forever mycopd Introducing mycopd, from my mhealth. mycopd is the most comprehensive, user friendly and intuitive COPD App available on any device. Built by COPD experts, and externally

More information

Over the last several years various national and

Over the last several years various national and Recommendations for the Management of COPD* Gary T. Ferguson, MD, FCCP Three sets of guidelines for the management of COPD that are widely recognized (from the European Respiratory Society [ERS], American

More information

American Thoracic Society (ATS) Perspective

American Thoracic Society (ATS) Perspective National Surveillance System for Chronic Lung Disease (CLD): American Thoracic Society (ATS) Perspective Gerard J. Criner, M.D. Chronic Obstructive Pulmonary Disease (COPD) l Definition: Group of chronic

More information

UNDERSTANDING COPD MEDIA BACKGROUNDER

UNDERSTANDING COPD MEDIA BACKGROUNDER UNDERSTANDING COPD MEDIA BACKGROUNDER What is COPD? Chronic Obstructive Pulmonary Disease (COPD) also called emphysema and/or chronic obstructive bronchitis* is a preventable lung disease caused by the

More information

Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research

Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Asthma and COPD in older people lumping or splitting? Christine Jenkins Concord Hospital Woolcock Institute of Medical Research Concord Hospital Woolcock Institute of Medical Research Joe has asthma What

More information

Hull and East Riding. Chronic Obstructive Pulmonary. Disease (COPD) Equity Audit

Hull and East Riding. Chronic Obstructive Pulmonary. Disease (COPD) Equity Audit Hull and East Riding Chronic Obstructive Pulmonary Disease (COPD) Equity Audit December 2010 Robert Sheikh Iddenden, Andrew Taylor, Jenny Walker Hull and East Riding Chronic Obstructive Pulmonary Disease

More information

Endobronchial valve insertion to reduce lung volume in emphysema

Endobronchial valve insertion to reduce lung volume in emphysema NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Endobronchial valve insertion to reduce lung volume in emphysema Emphysema is a chronic lung disease that

More information

Managing COPD. Richard EK Russell Imperial College London, UK. Paul A Ford Imperial College London, UK

Managing COPD. Richard EK Russell Imperial College London, UK. Paul A Ford Imperial College London, UK Managing COPD Managing COPD Richard EK Russell Imperial College London, UK Paul A Ford Imperial College London, UK Peter J Barnes National Heart and Lung Institute, Imperial College London, London, UK

More information

COPD in primary care: reminder and update

COPD in primary care: reminder and update COPD in primary care: reminder and update Managing COPD continues to be a major feature of primary care, particularly in practices with a high proportion of M ori and Pacific peoples. COPDX clinical practice

More information

Yorkshire & Humber Respiratory Programme Report

Yorkshire & Humber Respiratory Programme Report 2013 NHS Harrogate & Rural District Clinical Commissioning Group Yorkshire & Humber Respiratory Programme Report This report has been produced by the Yorkshire & Humber Respiratory Team. It highlights

More information

Living well with COPD

Living well with COPD This factsheet aims to show people with chronic obstructive pulmonary disease (COPD) and their friends and family how they can live a full life with this disease. What is COPD? COPD is a condition that

More information

Report Respiratory disease in England and Wales

Report Respiratory disease in England and Wales Report Respiratory disease in England and Wales From the Department of Clinical Epidemiology, National Heart and Lung Institute, London* Introduction There has been concern in recent years about the low

More information

Number of records submitted: 14,750 Number of participants: Part 1 = 146 hospitals (120 trusts); Part 2 = 140 hospitals (119 trusts)

Number of records submitted: 14,750 Number of participants: Part 1 = 146 hospitals (120 trusts); Part 2 = 140 hospitals (119 trusts) British Thoracic Society Smoking Cessation Audit Report Smoking cessation policy and practice in NHS hospitals National Audit Period: 1 April 31 May 2016 Dr Sanjay Agrawal and Dr Zaheer Mangera Number

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE 1 Guideline title SCOPE Bronchiolitis: diagnosis and management of bronchiolitis in children. 1.1 Short title Bronchiolitis in children 2 The remit The

More information

exacerbation has greater impact on functional status than frequency of exacerbation episodes.

exacerbation has greater impact on functional status than frequency of exacerbation episodes. Original Article Singapore Med J 2011, 52(12) 894 Changes in the BODE index, exacerbation duration and hospitalisation in a cohort of COPD patients Bu X N, Yang T, Thompson M A, Hutchinson A F, Irving

More information

COPD: A Renewed Focus. Disclosures

COPD: A Renewed Focus. Disclosures COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss

More information

Self-Management Plan for COPD

Self-Management Plan for COPD Self-Management Plan for COPD This is your personal management plan. Bring it with you every time you see a nurse or doctor about your COPD The aim of this plan is to help you have better control of your

More information

National COPD Audit Programme

National COPD Audit Programme National COPD Audit Programme Planning for every breath Primary Care Audit (Wales) 2015-17 Findings and quality improvement The audit programme partnership Working in strategic partnership: Supported by:

More information

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH

More information

roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd

roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd 06 August 2010 (Issued 10 September 2010) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?

ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,

More information

Care Bundle. Adult patients with COPD

Care Bundle. Adult patients with COPD Care Bundle Adult patients with COPD Version 2 July 2014 What is a care bundle? A care bundle is a set of interventions that, when used together, significantly improve patient outcomes. The measures chosen

More information

Interventional procedures guidance Published: 20 December 2017 nice.org.uk/guidance/ipg600

Interventional procedures guidance Published: 20 December 2017 nice.org.uk/guidance/ipg600 Endobronchial valve insertion to reduce lung volume in emphysema Interventional procedures guidance Published: 20 December 2017 nice.org.uk/guidance/ipg600 Your responsibility This guidance represents

More information

INITIATING A COPD CLINIC: PROTOCOL & ASSESSMENT

INITIATING A COPD CLINIC: PROTOCOL & ASSESSMENT COPD Resource Pack Section 2A INITIATING A COPD CLINIC: PROTOCOL & ASSESSMENT In this section: 1. Initiating a COPD Clinic 2. Equipment for a COPD Clinic 3. Primary Care Chronic Obstructive Pulmonary Disease

More information

COPD Management in LTC: Presented By: Jessica Denney RRT

COPD Management in LTC: Presented By: Jessica Denney RRT COPD Management in LTC: Presented By: Jessica Denney RRT Sponsored by Z & D Medical Services, Diamond Sponsor Seizing Opportunities to Provide Individualized Treatment and Device Selection for your COPD

More information

HEALTH NEEDS ASSESSMENT: DISEASES OF THE RESPIRATORY SYSTEM. A report assessing the respiratory health need of the population of Bolton

HEALTH NEEDS ASSESSMENT: DISEASES OF THE RESPIRATORY SYSTEM. A report assessing the respiratory health need of the population of Bolton EXECUTIVE SUMMARY HEALTH NEEDS ASSESSMENT: DISEASES OF THE RESPIRATORY SYSTEM January 2009 A report assessing the respiratory health need of the population of Bolton AUTHOR Mark Cook Public Health Intelligence

More information

SMOKING CESSATION. Why bother?

SMOKING CESSATION. Why bother? SMOKING CESSATION Why bother? Supporting policies COPD A disease characterised by airflow obstruction. It is usually progressive, not fully reversible and does not change markedly over several months.

More information

Screening for chronic obstructive pulmonary disease (COPD) in the general adult population

Screening for chronic obstructive pulmonary disease (COPD) in the general adult population Screening for chronic obstructive pulmonary disease (COPD) in the general adult population External review against programme appraisal criteria for the UK National Screening Committee Version: FINAL Author:

More information

COPD COPD. C - Chronic O - Obstructive P - Pulmonary D - Disease OBJECTIVES

COPD COPD. C - Chronic O - Obstructive P - Pulmonary D - Disease OBJECTIVES COPD C - Chronic O - Obstructive P - Pulmonary D - Disease 1 OBJECTIVES Following this presentation the participant should be able to demonstrate understanding of chronic lung disease by successful completion

More information

Management of acute asthma in children in emergency department. Moderate asthma

Management of acute asthma in children in emergency department. Moderate asthma 152 Moderate asthma SpO2 92% No clinical features of severe asthma NB: If a patient has signs and symptoms across categories, always treat according to their most severe features agonist 2-10 puffs via

More information

Oxygen and ABG. Dr Will Dooley

Oxygen and ABG. Dr Will Dooley Oxygen and ABG G Dr Will Dooley Oxygen and ABGs Simply in 10 cases Recap of: ABG interpretation Oxygen management Some common concerns A-a gradient Base Excess Anion Gap COPD patients CPAP/BiPAP First

More information

Chronic Obstructive Pulmonary Disease, shortened to COPD, is an umbrella term for a group of conditions which cause long-term damage to the airways.

Chronic Obstructive Pulmonary Disease, shortened to COPD, is an umbrella term for a group of conditions which cause long-term damage to the airways. 10 Common QuESTIonS AbouT CoPD Chronic Obstructive Pulmonary Disease, shortened to COPD, is an umbrella term for a group of conditions which cause long-term damage to the airways. COPD includes: chronic

More information

OBSERVATION UNIT ASTHMA PATHWAY OUTLINE Westmoreland Hospital PAGE 1 OF 5

OBSERVATION UNIT ASTHMA PATHWAY OUTLINE Westmoreland Hospital PAGE 1 OF 5 PAGE 1 OF 5 Exclusion Criteria: (Reason to admit to hospital) A. New EKG changes except sinus tachycardia B. Respiratory Rate > 40 C. Signs/symptoms of Heart Failure D. Impending respiratory failure or

More information

COPD Challenge CASE PRESENTATION

COPD Challenge CASE PRESENTATION Chronic obstructive pulmonary disease (COPD) exacerbations may make up more than 10% of acute medical admissions [1], and they are increasingly recognised as a cause of significant morbidity and mortality

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #51 (NQF 0091): Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

More information

UK National Screening Committee. Adult screening for COPD. 29 th June 2018

UK National Screening Committee. Adult screening for COPD. 29 th June 2018 UK National Screening Committee Adult screening for COPD 29 th June 2018 Aim 1. To ask the UK National Screening Committee (UK NSC) to make a recommendation, based on the evidence presented in this document,

More information

Bridges to Excellence Chronic Obstructive Pulmonary Disease Care Recognition Program Guide

Bridges to Excellence Chronic Obstructive Pulmonary Disease Care Recognition Program Guide Bridges to Excellence Chronic Obstructive Pulmonary Disease Care Recognition Program Guide Altarum Bridges to Excellence 3520 Green Court, Suite 300 Ann Arbor, MI 48105 bte@altarum.org www.bridgestoexcellence.org

More information

Design - Multicentre prospective cohort study. Setting UK Community Pharmacies within one CCG area within the UK

Design - Multicentre prospective cohort study. Setting UK Community Pharmacies within one CCG area within the UK Enabling Patient Health Improvements through COPD (EPIC) Medicines Optimisation within Community Pharmacy: a prospective cohort study Abstract Objectives To improve patients ability to manage their own

More information

Yorkshire & Humber Respiratory Programme Report. NHS Hambleton, Richmondshire and Whitby Clinical Commissioning Group

Yorkshire & Humber Respiratory Programme Report. NHS Hambleton, Richmondshire and Whitby Clinical Commissioning Group 2013 NHS Hambleton, Richmondshire and Whitby Clinical Commissioning Group Yorkshire & Humber Respiratory Programme Report This report has been produced by the Yorkshire & Humber Respiratory Team. It highlights

More information

National COPD Audit Programme

National COPD Audit Programme National COPD Audit Programme Planning for every breath National Chronic Obstructive Pulmonary Disease (COPD) Audit Programme: Primary care audit (Wales) 2015 17 Data analysis and methodology Section 2:

More information

Rosemary Plum Prescriptive Solutions Ltd SIMPLE Respiratory 2015

Rosemary Plum Prescriptive Solutions Ltd SIMPLE Respiratory 2015 + A SERVICE FOR COMMUNITY PHARMACY Rosemary Plum Prescriptive Solutions Ltd + n Why Pharmacy? High patient footfall 450 diagnosed asthma patients Walk-in service Medicines skills and expertise Structured

More information

An Update in COPD John Hurst PhD FRCP

An Update in COPD John Hurst PhD FRCP An Update in COPD John Hurst PhD FRCP Reader in Respiratory Medicine / Honorary Consultant University College London / Royal Free London NHS Foundation Trust j.hurst@ucl.ac.uk What s new in COPD papers

More information

Self-management plan for COPD

Self-management plan for COPD Sheffield Clinical Commissioning Group Sheffield Teaching Hospitals NHS Foundation Trust Self-management plan for COPD This is your personal management plan The aim of the plan is to help you have better

More information

A whistle stop tour of Respiratory Medicine and what the RUH & IMPACT offer

A whistle stop tour of Respiratory Medicine and what the RUH & IMPACT offer A whistle stop tour of Respiratory Medicine and what the RUH & IMPACT offer Jay Suntharalingam, Respiratory Physician, RUH Claire Bullard, IMPACT Team Leader, Sirona Outline Respiratory 5 year strategy

More information

Page 126. Type of Publication: Original Research Paper. Corresponding Author: Dr. Rajesh V., Volume 3 Issue - 4, Page No

Page 126. Type of Publication: Original Research Paper. Corresponding Author: Dr. Rajesh V., Volume 3 Issue - 4, Page No ISSN- O: 2458-868X, ISSN P: 2458 8687 Index Copernicus Value: 49. 23 PubMed - National Library of Medicine - ID: 101731606 SJIF Impact Factor: 4.956 International Journal of Medical Science and Innovative

More information

Optimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center

Optimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center Optimum COPD Care in 2010 Why Not Now? David E. Taylor, M.D. Pulmonary/Critical Care Ochnser Medical Center dtaylor@ochsner.org Observations from Yesterday EPIC is epidemic No EMR No Way!!! Accountability/Benchmarking

More information